TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company’s pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.